# Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.

> **NCT00102128** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company**

## Conditions studied

- Ischemic Heart Failure
- Ischemic Heart Disease
- Ischemic Cardiomyopathy

## Interventions

- **DRUG:** Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)

## Key facts

- **NCT ID:** NCT00102128
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-11
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** — (—)
- **Why stopped:** DMC recommended stop
- **Last updated:** 2015-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102128, "Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00102128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*